Wednesday, September 17, 2025 9/17/2025

Pregnancy as a Window to the Future: Outcomes of Antihypertensive Therapy and Superimposed Preeclampsia in Pregnant Women with Mild Chronic Hypertension (CHAP Maternal Follow-up Study)

Award Number: R01HL120338
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/01/2014
PERIOD OF PERFORMANCE END DATE: 08/31/2026

Group Awards By:

View Award Description

Pregnancy as a Window to the Future: Outcomes of Antihypertensive Therapy and Superimposed Preeclampsia in Pregnant Women with Mild Chronic Hypertension (CHAP Maternal Follow-up Study) - PROJECT SUMMARY/ABSTRACT The large randomized multicenter Chronic Hypertension and Pregnancy (CHAP) trial (2015-2021) was designed to evaluate the short-term benefits and safety of pharmacologic treatment of pregnant women with mild chronic hypertension (CHTN). This proposed CHAP Maternal Follow-Up project (2021-2026) is a follow-up study of the well-characterized women in CHAP to address the critical knowledge gaps regarding whether future long-term cardiovascular disease (CVD) and other outcomes are associated with 1) antihypertensive therapy use early in pregnancy and 2) the development of superimposed preeclampsia (SI PRE). CHTN is the most common major medical disorder seen in pregnancy, is most often mild (i.e. BP <160/110 mmHg), and associated with adverse outcomes, including preeclampsia, death, preterm birth and small for gestational age (SGA) infants (birth weight <10th percentile). Whereas antihypertensive therapy is a priority for the general population, the American College of Obstetricians and Gynecologists (ACOG), recommends withholding antihypertensive therapy during pregnancy unless CHTN is severe (BP≥160/110 mm Hg) due to uncertain benefits and concern that therapy may increase the risk of SGA infants. An international controversy regarding optimal treatment during pregnancy will be informed by these data on long-term outcomes. Whereas preeclampsia in women without CHTN increases their future risk of CHTN and CVD, the long-term effects of SI PRE and antihypertensive therapy in women with preexisting CHTN are uncertain. During this proposed 5- year project, our consortium of up to 60 sites, will follow-up the CHAP participants every 6 months (in-person or remotely, review medical records and administer questionnaires) to obtain interval history, serial BPs and outcome data, and collect bio-specimens. We anticipate 1804 (75%) of the 2404 in CHAP will be studied to address the following Specific Aims: Specific Aim 1: Test the hypothesis that antihypertensive therapy for mild CHTN during pregnancy to achieve a BP goal <140/90 compared with no treatment reduces the frequency of maternal CVD outcomes 5 to 10 years postpartum, including the primary composite of severe CHTN (a marker of future CVD), heart failure, stroke, myocardial infarction/angina, renal failure, venous thromboembolism (VTE) or death. Specific Aim 2: Test the hypothesis that the development of SI PRE in pregnant women with mild CHTN increases the risk of maternal CVD outcomes 5 to 10 years postpartum, including the primary composite of severe CHTN, heart failure, stroke, myocardial infarction/angina, renal failure, VTE and death. Specific Aim 3 (Exploratory): Test whether available components of the ACC/AHA ASCVD risk score (age, race-ethnicity, diabetes mellitus, smoking status, baseline BP, pre-pregnancy treatment) and pregnancy data (treatment and SI PRE) in women with mild CHTN predict maternal CVD outcomes 5-10 years postpartum. We will also collect and store maternal blood and urine for future biomarker and biological studies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $2,007,149 )
2025	2025	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	11	8/18/2025	NON-COMPETING CONTINUATION	$2,007,149
														Subtotal = $2,007,149

Issue Date FY: 2024 ( Subtotal = $1,976,808 )
2024	2024	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH STREET	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	10	8/16/2024	NON-COMPETING CONTINUATION	$1,976,808
														Subtotal = $1,976,808

Issue Date FY: 2023 ( Subtotal = $2,046,886 )
2023	2023	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	001	9	8/23/2023	NON-COMPETING CONTINUATION	$2,046,886
2023	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	8	10/17/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = $2,046,886

Issue Date FY: 2022 ( Subtotal = $4,365,419 )
2022	2022	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	004	8	8/17/2022	NON-COMPETING CONTINUATION	$2,103,237
2022	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	003	7	6/29/2022	COMPETING CONTINUATION	$0
2022	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	001	7	3/9/2022	COMPETING CONTINUATION	-$2,302,071
2022	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	002	7	4/29/2022	COMPETING CONTINUATION	$2,262,182
2022	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	7	1/27/2022	COMPETING CONTINUATION	$2,302,071
														Subtotal = $4,365,419

Issue Date FY: 2021 ( Subtotal = $2,352,905 )
2021	2021	UNIVERSITY OF ALABAMA AT BIRMINGHAM	701 S 20TH ST	BIRMINGHAM	AL	35294	JEFFERSON	USA	Cardiovascular Diseases Research	000	7	8/6/2021	COMPETING CONTINUATION	$2,352,905
														Subtotal = $2,352,905

Grand Total All Awards = $12,749,167

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Pregnancy as a Window to the Future: Outcomes of Antihypertensive Therapy and Superimposed Preeclampsia in Pregnant Women with Mild Chronic Hypertension (CHAP Maternal Follow-up Study)

Award Number: R01HL120338

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/01/2014

PERIOD OF PERFORMANCE END DATE: 08/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer